Provectus Biopharmaceuticals, Inc.
PVCT
$0.0923
-$0.0046-4.75%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -136.29% | -19.79% | -68.02% | 24.03% | 14.49% |
| Total Depreciation and Amortization | -77.27% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 10,764.71% | 0.85% | 1.72% | 0.87% | -19.01% |
| Change in Net Operating Assets | -55.97% | 519.06% | 112.68% | -726.33% | 1,031.58% |
| Cash from Operations | -61.42% | 25.91% | 26.99% | -86.12% | 27.01% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 27.82% | -0.75% | -30.79% | 287.20% | -72.22% |
| Total Debt Repaid | 18.52% | 6.67% | 56.66% | -286.16% | 41.05% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 33.76% | 0.07% | -24.59% | 287.45% | -75.35% |
| Foreign Exchange rate Adjustments | -280.00% | 150.00% | 133.33% | 97.47% | -1,228.57% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -600.00% | 114.35% | 34.28% | 31.14% | -851.76% |